2.53
+6.30%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rocket Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Rocket Pharmaceuticals is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RCKT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $223.1m. At that date it held total assets of $330.4m and shareholders' equity of $277.2m.
We are a fully integrated, late-stage biotechnology company focused on the development, manufacturing, and potential commercialization of genetic therapies for rare and often fatal diseases with high unmet medical need. Our innovative multi-platform approach is designed to create best-in-class gene therapy product candidates aimed at correcting the underlying genetic causes of complex inherited cardiomyopathies and related disorders, with the potential to deliver transformative and durable clinical benefits. Our platform is supported by in-house research and development capabilities and current cGMP manufacturing facilities that enable end-to-end control of clinical production, process development, and scale-up for potential commercialization.
We seek to bring hope and relief to patients with devastating, undertreated and rare diseases through the development and commercialization of potentially curative first-in-class gene therapies. As a fully integrated, late-stage biotechnology company, we have the resources and opportunity to generate a portfolio of highly differentiated and potentially first-in-class or best-in-class genetic medicines.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Feb 2015
- Employees
- 202
- Website
- rocketpharma.com ↗
- Head office
- 350 FIFTH AVENUE, NEW YORK, NY, 10118
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Roderick WongChairman of the Board$409,981
- Dr. Kinnari PatelPresident, Head of Research and Development$6.7m
- Dr. Gaurav ShahChief Executive Officer, Director, since 2018$6.8m
- Mr. Martin WilsonInterim Principal Financial Officer, Senior Vice President, General Counsel$2.1m
- Mr. Christopher StevensChief Operating Officer
- Mr. Raj PrabhakarSenior Vice President, Chief Business Officer$2.8m
- Mr. John MilitelloPrincipal Accounting Officer, Vice President - Finance, Treasurer$1.2m
- Ms. Sarbani ChaudhuriChief Commercial and Medical Affairs Officer
- Dr. Jonathan SchwartzChief Medical and Gene Therapy Officer$2.4m
- Mr. Peter FongDirector
- Dr. Elisabeth BjorkIndependent Director$416,926
- Mr. Carsten BoessIndependent Director$429,467
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 23
- Social
- 73
- Governance
- 49
- Direct emissions (scope 1)
- 529 t
- Energy emissions (scope 2)
- 1,889 t
- Women in the workforce
- 50%
- Carbon reduction policy
- No
- Human rights policy
- No
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.